RareStone Inc Announces Submission of New Drug Application (NDA) of Wakix® (pitolisant) for narcolepsy with and without cataplexy in China prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Published: May 12, 2021
CAMBRIDGE, Mass. and SHANGHAI, May 12, 2021 /PRNewswire/ Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has signed a licensing agreement with Diurnal Group plc (AIM: DNL), a specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases. The deal provides Citrine with exclusive rights to develop and commercialize Efmody
® (hydrocortisone modified-release hard capsules – development name Chronocort
®) in the Greater China market. In January, Citrine signed a licensing agreement with Dirunal Group for Alkindi,
® the first preparation of hydrocortisone specifically designed for use in children suffering from pediatric adrenal insufficiency (AI) and congenital adrenal hyperplasia (CAH).
$1.0 million and will receive
$28.75 million in additional cash payments upon achievement of certain regulatory milestones and sales milestones based on annual sales thresholds. Diurnal will also receive tiered royalties on sales ranging from low to mid double-digits.
Citrine is a therapeutics platform company focused on the
Greater China market that was co-founded by Vivo Capital, F-Prime Capital and Eight Roads Ventures. Citrine is focused on creating a therapeutic platform to deliver rare disease drugs to the Chinese market and to develop the first ever rare disease ecosystem in the country. The Company signed an original licensing agreement with Citrine in
/PRNewswire/ Citrine Medicine, a China-based rare disease therapeutics company, today announced that it has signed a licensing agreement with Diurnal Group.
Citrine Medicine and Sinopharm Group Announce Strategic Partnership to Broaden and Accelerate Access to Rare Disease Drugs in China
Collaboration to focus on establishing supply chain and securing distribution channels for delivering rare disease therapies to patients across China
News provided by
Share this article
Share this article
BOSTON and SHANGHAI, April 19, 2021 /PRNewswire/ Citrine Medicine, a China-based rare disease therapeutics company, and Sinopharm Group, a Chinese pharmaceutical company, today announced a strategic partnership to accelerate the commercialization of rare disease drugs in China. The two companies will work together to build a rare disease ecosystem in China and enable the availability of more rare disease therapies to Chinese patients in need.